Product Information
FENOFIBRATE 150 MG CAPSULE is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $5.3029 per EA under NDC 62559046190. Its NADAC has been published 542 times since May 18, 2016.
FDA first approved this application on Jan 11, 2006.
The High Outlier badge above means this manufacturer's average price in the fenofibrate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
150 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
62559046190
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA021612FDA Approved
1/11/2006
On Market Since
4/13/2016
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 150 MG CAPSULE has been published 542 times since May 18, 2016, and over the history we have for it it has risen 21.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.3029 per EA |
|---|---|
| All-time high | $5.8133 (Jan 11, 2017) |
| All-time low | $4.3561 (May 18, 2016) |
| 52-week high | $5.4577 |
| 52-week low | $5.2752 |
| Median price | $5.5587 |
| Average price | $5.4791 |
| Largest weekly change | +12.5% (Aug 17, 2016) |
| Weeks tracked | 542 |
| Tracking since | May 18, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the fenofibrate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 150 MG CAPSULE, manufactured by ANI Pharmaceuticals, Inc., is $5.3029 per EA (NDC 62559046190), effective Sep 30, 2026.
How has the price of FENOFIBRATE 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 150 MG CAPSULE has risen 21.7%. It has been tracked across 542 weekly CMS publications since May 18, 2016.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 150 MG CAPSULE?
Since May 18, 2016, the NADAC for FENOFIBRATE 150 MG CAPSULE has ranged from a low of $4.3561 (May 18, 2016) to a high of $5.8133 (Jan 11, 2017), with a median of $5.5587 per EA.
Are there cheaper alternatives to FENOFIBRATE 150 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of FENOFIBRATE 150 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FENOFIBRATE 150 MG CAPSULE?
FENOFIBRATE 150 MG CAPSULE (NDC 62559046190) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.